NCT07503002Not yet recruitingPhase 1
Shortened LSD Intervention for Major Depressive Disorder
Source: ClinicalTrials.gov · Last updated 3 Nov 2026
Brief summary (registry, in English)
The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 25 Mar 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- Johns Hopkins University
- Diseases
- Depression
- NCT number
- NCT07503002
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- From 1 Dec 2026 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently taking antipsychotics, or MAO inhibitors
- Patients taking antidepressant medications and unable to taper
- Moderate or strong CYP2D6 inhibitor antidepressants must undergo a washout period of 4 weeks or five half-lives prior to treatment
- Currently taking CYP2D6 inhibitor other than an antidepressant that will be tapered
- Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UGT1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag
Other illness
- Epilepsy
- Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
- Have a seizure disorder, multiple sclerosis, history of significant head trauma, CNS tumor, movement disorders or any neurodegenerative condition
- Morbidly obese (\>100 lbs. above ideal body weight, or BMI \>=40, or BMI \>=35 with high blood pressure or diabetes)
- Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (including substance-induced), Bipolar I or II Disorder or Major
- Have a first degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or Bipolar I Disorder.
Lab values
- Cardiovascular conditions: hypertension with resting blood pressure systolic \>139 or diastolic \>89, angina, heart rate \> 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc \> 450), TIA in the last 6 months stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy
Other
- Women who are pregnant, nursing, or not practicing an effective means of birth control
- Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal
- Body weight \< 45 kg
- Significant acute adverse reaction (e.g., dystonia) to an antipsychotic
- Depression with psychotic features
Who the study is looking for
- Have given written informed consent
- Meet DSM-5 criteria for MDD
- MADRS \>= 28 at screening Can read, write, and speak English fluently
- Be judged by study team clinicians to be at low risk for suicidality
Age in the registry: 21 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Center for Psychedelic and Consciousness Research Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.